ANAB
NASDAQ HealthcareAnaptysBio, Inc. - Common Stock
Biotechnology
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
๐ Market Data
| Price | $48.64 |
|---|---|
| Volume | 414,328 |
| Market Cap | 1.45B |
| Beta | 0.450 |
| RSI (14-Day) | 57.0 |
| 200-Day MA | $50.33 |
| 50-Day MA | $51.93 |
| 52-Week High | $72.36 |
| 52-Week Low | $20.18 |
| Forward P/E | 10.72 |
| Price / Book | 136.63 |
๐ฏ Investment Strategy Scores
ANAB scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (56/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Moon Shot (28/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ANAB in your text
Paste any article, transcript, or post โ the tool will extract ANAB and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-10-29.